STOCK TITAN
  1. Home
  2. Sec-filings
  3. KTTA
  4. [EFFECT] Pasithea Therapeutics Corp. SEC Filing

[EFFECT] Pasithea Therapeutics Corp. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 27, 2026
Accession Number: 0001213900-26-007469
Submission Type: POS AM
CIK: 0001841330
Company Name: Pasithea Therapeutics Corp.
File Number: 333-271010

Source: View Original Filing on SEC EDGAR

Stock KTTA logo
Pasithea Therapeutics Corp

NASDAQ:KTTA

KTTA Rankings

#6060 Ranked by Market Cap
N/A Ranked by Dividends

KTTA Latest News

Jan 13, 2026
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
Dec 2, 2025
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Nov 28, 2025
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
Nov 25, 2025
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS
Nov 24, 2025
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

KTTA Latest SEC Filings

Jan 28, 2026
[8-K] Pasithea Therapeutics Corp. Reports Material Event
Jan 26, 2026
[POS AM] Pasithea Therapeutics Corp. SEC Filing
Dec 15, 2025
[8-K] Pasithea Therapeutics Corp. Reports Material Event
Nov 26, 2025
[S-1/A] Pasithea Therapeutics Corp. Amends IPO Registration Statement
Nov 25, 2025
[8-K] Pasithea Therapeutics Corp. Reports Material Event

KTTA Stock Data

19.55M
22.72M
3.26%
10.95%
1.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI BEACH